benserazide has been researched along with Hyperactivity, Motor in 6 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dyskinesias, confusional state and "on-off" phenomenon increased with time, whereas gastric trouble diminished." | 2.65 | [Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)]. ( Del Pesce, M; Di Bella, P; Forastieri, L; Paggi, A; Quattrini, A, 1979) |
| " Based on the results of rotational behavior and forelimb hyperkinesia in Week 5, the rats were allocated to three treatment groups (saline and two dosing rates of piclozotan set at 0." | 1.36 | Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. ( Inoue, T; Koyama, M; Ogata, A; Tani, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knopp, C | 1 |
| Häusler, M | 1 |
| Müller, B | 1 |
| Damen, R | 1 |
| Stoppe, A | 1 |
| Mull, M | 1 |
| Elbracht, M | 1 |
| Kurth, I | 1 |
| Begemann, M | 1 |
| Alachkar, A | 1 |
| Brotchie, JM | 1 |
| Jones, OT | 1 |
| Tani, Y | 1 |
| Ogata, A | 1 |
| Koyama, M | 1 |
| Inoue, T | 1 |
| Liu, DK | 1 |
| Quattrini, A | 1 |
| Paggi, A | 1 |
| Forastieri, L | 1 |
| Del Pesce, M | 1 |
| Di Bella, P | 1 |
| Gerlach, J | 1 |
2 trials available for benserazide and Hyperactivity, Motor
| Article | Year |
|---|---|
[Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)].
Topics: Adult; Benserazide; Brain; Carbidopa; Clinical Trials as Topic; Confusion; Electrocardiography; Elec | 1979 |
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1976 |
4 other studies available for benserazide and Hyperactivity, Motor
| Article | Year |
|---|---|
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Child; Consanguinity; Dopamine Agents; Dr | 2019 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxyla | 2010 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Ag | 2010 |
[Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
Topics: Adult; Benserazide; Electrocardiography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; M | 1980 |